Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Intercept Pharmaceuticals, Inc.

 Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against
                       Intercept Pharmaceuticals, Inc.

PR Newswire

NEW YORK, Feb. 24, 2014

NEW YORK, Feb. 24, 2014 /PRNewswire/ -- Bernstein Liebhard LLP today announced
that a class action has been commenced in the United States District Court for
the Southern District of New York on behalf of purchasers (the "Class") of
securities of Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ: ICPT)
during the period of January 9, 2014 and January 10, 2014 (the "Class

Bernstein Liebhard LLP

The complaint charges Intercept and certain of its officers and directors with
violations of the Securities Exchange Act of 1934. Intercept is a
pharmaceutical company that has been developing and trying to bring to market
new clinical drugs. The Company's primary drug compound, known as obeticholic
acid ("OCA"), is in various phases of clinical development, primarily for the
purpose of treating chronic liver diseases, including non-alcoholic
steatohepatitis ("NASH").

The complaint alleges that on January 9, 2014 and January 10, 2014, Intercept
announced that its Phase 2 trial of OCA for the treatment of NASH had been
stopped early for efficacy based on an interim analysis that showed that the
efficacy endpoint of the trial had been met. As a result of the Company's
announcements, the Company's stock price skyrocketed from a January 8, 2014
close of $72.39 per share to a January 10, 2014 close of $445.83 per share.

Then, on Friday, January 10, 2014, after the markets closed, the National
Institutes of Health's ("NIH") National Institute of Diabetes and Digestive
and Kidney Diseases issued a press release stating that while the efficacy
primary endpoint for OCA in the Phase 2 study had already been met,
participants in the study who received the drug suffered disproportionate
levels of lipid abnormalities. The complaint alleges that, as a result of the
NIH's January 10, 2014 disclosure of OCA's safety risks, Intercept's stock
price dropped over $81 per share – a decline of 18.2% – from $445.83 to
$364.36 per share on Monday, January 13, 2014, and continued to fall on
January 14, 2014 to a close of $255.12 per share, as investors continued to
digest and react to this negative news.

Plaintiffs seek to recover damages on behalf of all Class members who invested
in Intercept securities during the Class Period. If you invested in Intercept
securities as described above, and either lost money on the transaction or
still hold the security, you may wish to join in this action to serve as lead
plaintiff. In order to do so, you must meet certain requirements set forth in
the applicable law and file appropriate papers no later than April 22, 2014.

A "lead plaintiff" is a representative party that acts on behalf of other
class members in directing the litigation. In order to be appointed lead
plaintiff, the court must determine that the class member's claim is typical
of the claims of other class members, and that the class member will
adequately represent the class. Under certain circumstances, one or more
class members may together serve as lead plaintiff. Your ability to share in
any recovery is not, however, affected by the decision whether or not to serve
as a lead plaintiff. You may retain Bernstein Liebhard LLP, or other counsel
of your choice, to serve as your counsel in this action.

If you are interested in discussing your rights as an Intercept shareholder
and/or have information relating to the matter, please contact Joseph R.
Seidman, Jr. at (877) 779-1414 or

Bernstein Liebhard LLP has pursued hundreds of securities, whistleblower law
and shareholder rights cases and recovered over $3 billion for its clients.
It has been named to The National Law Journal's "Plaintiffs' Hot List" in each
of the last eleven years.

You can obtain a copy of the complaint from the clerk of the court for the
United States District Court for the Southern District of New York.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible
for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New
York, New York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of Connecticut is Michael S. Bigin. Prior results
do not guarantee or predict a similar outcome with respect to any future

Contact Information
Joseph R. Seidman, Jr.
Bernstein Liebhard LLP
(212) 779-1414


SOURCE Bernstein Liebhard LLP

Press spacebar to pause and continue. Press esc to stop.